Given the timeline of this study, longitudinal studies are needed to determine whether SARS-CoV-2-specific IgA, IgM, and IgG will persist for a longer time in patients with acute COVID-19 than in asymptomatic patients. The gene discussed is CD79A; the disease is COVID-19.